96-Week Resistance Analyses of Rilpivirine in Treatment-Naive,HIV-1-Infected Adults from the Echo and Thrive Phase Iii Trials

Janssen-Cilag US prescribing information for EDURANT^® (rilpivirine) tablets. (Updated December 2012. Accessed 20 February 2013.) Available from http://www.edurant.com/sites/default/files/EDURANT-PI.pdf.

Janssen-Cilag EU summary of product characteristics for EDURANT^® (rilpivirine) tablets. (Updated December 2012. Accessed 20 February 2013.) Available from http://www.medicines.org.uk/EMC/medicine/25490/SPC/Edurant+25+mg+tablets/#DOCREVISION.

Gilead Sciences full prescribing information COMPLERA™ (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) tablets. (Updated January 2013. Accessed 20 February 2013.) Available from http://www.gilead.com/pdf/complera_pi.pdf.

Gilead Sciences EVIPLERA 200 mg/25 mg/245 mg film-coated tablets summary of product characteristics. (Updated December 2012. Accessed 20 February 2013.) Available from http://www.medicines.org.uk/emc/medicine/25518/SPC/.

Cohen C.J. , Molina J.M. , Cahn P. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive, HIV-1-infected patients: pooled results from the Phase 3 double-blind, randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60: 33–42.

Molina J.M. , Cahn P. , Grinsztejn B. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a Phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238–246.

Cohen C.J. , Andrade-Villanueva J. , Clotet B. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a Phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229–237.

Cohen C. , Molina J.M. , Cassetti I. Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS 2013; 27: 939–950.

DHHS guidelines: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1–239. (Updated February 2013. Accessed 20 February 2013.) Available from http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.

EACS guidelines: EACS European Guidelines for treatment of HIV infected adults in Europe. Version 6.1. (Updated November 2012. Accessed 20 February 2013.) Available from http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6.1-2edition.pdf.

Li JZ, Paredes R, Ribaudo HJ. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305: 1327–1335.

Ibe S. , Sugiura W. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. Future Microbiol 2011; 6: 295–315.

Perno C.F. , Moyle G. , Tsoukas C. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol 2008; 80: 565–576.

Rimsky L. , Vingerhoets J. , Van Eygen V. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failures in the Phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012; 59: 39–46.

Vingerhoets J. , Rimsky L. , Van Eygen V. Preexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic response. Antivir Ther 2012; 18: 253–256.

Azijn H. , Tirry I. , Vingerhoets J. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54: 718–727.

Johnson V.A. , Calvez V. , Günthard H.F. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med 2011; 19: 156–164.

Tambuyzer L. , Azijn H. , Rimsky L.T. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. Antivir Ther 2009; 14: 103–109.

Haddad M. , Napolitano L. , Paquet A. Mutation Y188L of HIV-1 reverse transcriptase is strongly associated with reduced susceptibility to rilpivirine. 19th Conference on Retroviruses and Opportunistic Infections. 5–8 March 2012, Seattle, WA, USA. Abstract 695.

Picchio G.R. , Rimsky L.T. , Van Eygen V. Prevalence of rilpivirine resistance-associated mutations (RAMs) in US samples received for routine resistance testing. XIX International AIDS Conference. 22–27 July 2012, Washington DC, USA. Abstract TUPE047.

Lennox J.L. , Dejesus E. , Lazzarin A. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796–806.

Molina J.M. , Andrade-Villanueva J. , Echevarria J. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323–332.

González-Garcia J. , Cohen D. , Johnson M. Short communication: comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naive, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730. AIDS Res Hum Retroviruses 2010; 26: 841–845.

Bacheler L.T. , Antone E.D. , Kudish P. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000; 44: 2475–2484.

Tisdale M. , Kemp S.D. , Parry N.R. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993; 90: 5653–5656.

Maserati R. , De Silvestri A. , Uglietti A. Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine. AIDS 2010; 24: 1013–1018.

Kulkarni R. , Babaoglu K. , Lansdon E.B. The HIV-1 reverse transcriptase M184I mutation enhances the E128K-associated resistance to rilpivirine and decreases viral fitness. J Acquir Immune Defic Syndr 2012; 59: 47–54.

Xu H.T. , Asahchop E.L. , Oliveira M. Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol 2011; 85: 11300–11308.

Hu Z. , Kuritzkes D.R. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011; 85: 11309–11314.

Xu H.T. , Oliveira M. , Quashie P.K. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. J Virol 2012; 86: 8422–8431.

Fourati S. , Malet I. , Lambert S. E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. AIDS 2012; 26: 1619–1624.

Anta L. , Llibre J.M. , Poveda E. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS 2013; 27: 81–85.

Reinheimer C. , Doerr H.W. , Stürmer M. Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database. J Clin Virol 2012; 53: 248–250.

Van Eygen V. , Thys K. , Vingerhoets J. Deep sequencing analysis of rilpivirine virologic failures in the Phase III studies ECHO and THRIVE shows no association with the presence of minority resistance-associated variants at baseline. International Workshop on HIV & Hepatitis Virus Drug Resistance and Curative Strategies. 5–9 June 2012, Sitges, Barcelona, Spain. Abstract 27.

Rimsky L. , Van Eygen V. , Vingerhoets J. Similar prevalence of baseline HIV-1 minority variants among responders and virologic failures, as well as increased detection of HIV-1 minority variants at treatment-failure, in rilpivirine patients from the ECHO and THRIVE Phase III studies. XIX International AIDS Conference. 22–27 July 2012, Washington DC, USA. Abstract TUAB0302.

Nicot F. , Salioua A. , Raymond S. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection. J Clin Virol 2012; 55: 107–113.

Balamane M. , Varghesea V. , George L. Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine. Antimicrob Agents Chemother 2012; 56: 4522–4524.

Janssen P.A.J. , Lewi P.J. , Arnold E. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoetenyl]-2-6-dimethylphenyl]amino]-2-pyrimidinyl]amino]-benzonitrile (R278474, Rilpivirine). J Med Chem 2005; 48: 1901–1909.

Lansdon E.B. , Brendza K.M. , Hung M. Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design. J Med Chem 2010; 53: 4295–4299.

Thompson M.A. , Aberg J. , Hoy J. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society–USA Panel. JAMA 2012; 308: 387–402.